ReXceptor Overview

  • Founded
  • 2011
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

ReXceptor General Information


Developer of small molecule therapeutics designed to offer treatment of Alzheimer's disease. The company's therapeutics examines the efficacy of bexarotene on key Alzheimer's disease indicators, including brain amyloid beta and apolipoprotein E by administering a retinoid X receptor (RXR) agonist, enabling doctors to offer rapid reduction of soluble forms of amyloid that is associated with the reversal of memory and cognition over a few days.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Primary Office
  • 11000 Cedar Avenue
  • Suite 100
  • Cleveland, OH 44106
  • United States
+1 (216) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ReXceptor Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 01-Oct-2017 00.00 Completed Out of Business
4. Grant 01-Jan-2014 00000 00.00 Completed Clinical Trials - Phase 1
3. Early Stage VC 24-Apr-2013 00000 00.00 Completed Clinical Trials - Phase 1
2. Seed Round 25-Mar-2013 $400K $400K Completed Startup
1. Accelerator/Incubator Completed Startup
To view ReXceptor’s complete valuation and funding history, request access »

ReXceptor Executive Team (3)

Name Title Board Seat Contact Info
Michael Haag President & Chief Executive Officer
Gary Landreth Co-Founder
You’re viewing 2 of 3 executive team members. Get the full list »